Abstract:Pathological complete response (pCR) is an important factor for evaluating the efficacy of neoadjuvant treatment in patients with locally advanced rectal cancer (LARC), which is also associated with better survivals. Previous studies identified that pCR had a dose-effect relationship with the irradiation dose to the primary tumor. This study was designed to evaluate the efficacy and tolerance of image guided, concomitant dose escalation neoadjuvant radiotherapy in patients with LARC. Patients with mid-low LARC (cT3/T4, or cN+), treated with concomitant dose escalation neoadjuvant radiotherapy and surgery at our institute between September 2012 and December 2017 were enrolled. A dose of 45/50Gy in 25 fractions was delivered to the pelvis. The primary tumor received a dose of 56Gy at the same time. The concurrent chemotherapy regimen included capecitabine alone and Xelox. Surgery was performed at least six weeks after radiotherapy. Adjuvant chemotherapy was performed individualized. Overall survival (OS), disease free survival (DFS) and local control (LC) was calculated with Kaplan-Meier method. A total of 403 patients were enrolled in our study. The median follow-up duration was 36.1 months (range: 3.6-81.1 months). The 3-year and estimated 5-year OS, DFS, LC were 88.3% and 76.4%, 73.9% and 70.2%, 92.9% and 92.2%, respectively. After neoadjuvant radiotherapy, TME surgery was performed in 377 patients (93.5%), while 26 patients (6.5%) received TEM surgery. Downstaging was observed in 339 patients (90.6%) with T downstaging in 222 patients (59.4%) and N downstaging in 297 patients (79.4%). Ninety-six patients (23.8%) obtained pCR. Sphincter-preserving resection was performed in 326 patients (80.9%), and the actual sphincter-preserving rate was 62.8%. The incidence of grade 3 or greater acute hematologic, gastrointestinal and genitourinary toxicity were 9.5%, 4.2% and 2.5%, respectively. Forty-one patients (10.2%) developed surgery complications. Neoadjuvant concomitant dose escalation radiotherapy was well tolerated in patients with mid-low LARC, resulting in high rates of pCR, sphincter-preserving surgery and survival outcomes.

Image Guided Concomitant Dose Escalation Neoadjuvant Radiotherapy in Patients with Locally Advanced Mid-low Rectal Cancer